Revista médica de Chile
versión impresa ISSN 0034-9887
Gastrointestinal stromal tumors (GIS) are a heterogeneous group of tumors that express CD 117 molecule in their sur face. They may behave as benign tumors or be highly aggressive. A better survival ofpatients with these tumors has been achieved using the new molecular therapies such as imatinib mesylate, sunitinib and others. This review analyzes the prognostic factors of these tumors, their clinical features and the criteria for malignant behavior. The valué of therapeutic alternatives such as radiotherapy chemotherapy and the new molecular therapies are also discussed
Palabras clave : Gastrointestinal stromal tumors; Proein-tyrosine kinases; Proto-oncogene proteins.